The Gut-liver Axis in Hepatobiliary Diseases

Overview

Journal Inflamm Regen

Publisher Biomed Central

Date 2024 Jan 8

PMID 38191517

Authors

Masataka Ichikawa

Haruka Okada

Nobuhiro Nakamoto

Nobuhito Taniki

Po-Sung Chu

Takanori Kanai

Affiliations

Soon will be listed here.

Abstract

Recent advances in the analysis of intestinal bacteria have led to reports of variations in intestinal bacterial levels among hepatobiliary diseases. The mechanisms behind the changes in intestinal bacteria in various hepatobiliary diseases include the abnormal composition of intestinal bacteria, weakening of the intestinal barrier, and bacterial translocation outside the intestinal tract, along with their metabolites, but many aspects remain unresolved. Further research employing clinical studies and animal models is expected to clarify the direct relationship between intestinal bacteria and hepatobiliary diseases and to validate the utility of intestinal bacteria as a diagnostic biomarker and potential therapeutic target. This review summarizes the involvement of the microbiota in the pathogenesis of hepatobiliary diseases via the gut-liver axis.

Citing Articles

Bile acids as a key target: traditional Chinese medicine for precision management of insulin resistance in type 2 diabetes mellitus through the gut microbiota-bile acids axis.

Wang Y, Yu J, Chen B, Jin W, Wang M, Chen X Front Endocrinol (Lausanne). 2024; 15:1481270.

PMID: 39720247 PMC: 11666381. DOI: 10.3389/fendo.2024.1481270.

References

Dong F, Perdew G . The aryl hydrocarbon receptor as a mediator of host-microbiota interplay. Gut Microbes. 2020; 12(1):1859812. PMC: 7781536. DOI: 10.1080/19490976.2020.1859812. View

Bachem A, Makhlouf C, Binger K, de Souza D, Tull D, Hochheiser K . Microbiota-Derived Short-Chain Fatty Acids Promote the Memory Potential of Antigen-Activated CD8 T Cells. Immunity. 2019; 51(2):285-297.e5. DOI: 10.1016/j.immuni.2019.06.002. View

Perino A, Schoonjans K . Metabolic Messengers: bile acids. Nat Metab. 2022; 4(4):416-423. DOI: 10.1038/s42255-022-00559-z. View

Tedesco D, Thapa M, Chin C, Ge Y, Gong M, Li J . Alterations in Intestinal Microbiota Lead to Production of Interleukin 17 by Intrahepatic γδ T-Cell Receptor-Positive Cells and Pathogenesis of Cholestatic Liver Disease. Gastroenterology. 2018; 154(8):2178-2193. PMC: 5985208. DOI: 10.1053/j.gastro.2018.02.019. View

Peterson L, Artis D . Intestinal epithelial cells: regulators of barrier function and immune homeostasis. Nat Rev Immunol. 2014; 14(3):141-53. DOI: 10.1038/nri3608. View

Karlsen T, Folseraas T, Thorburn D, Vesterhus M . Primary sclerosing cholangitis - a comprehensive review. J Hepatol. 2017; 67(6):1298-1323. DOI: 10.1016/j.jhep.2017.07.022. View

Pushalkar S, Hundeyin M, Daley D, Zambirinis C, Kurz E, Mishra A . The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression. Cancer Discov. 2018; 8(4):403-416. PMC: 6225783. DOI: 10.1158/2159-8290.CD-17-1134. View

Tabibian J, Weeding E, Jorgensen R, Petz J, Keach J, Talwalkar J . Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study. Aliment Pharmacol Ther. 2013; 37(6):604-12. DOI: 10.1111/apt.12232. View

Sharma A, Roy A, Premkumar M, Verma N, Duseja A, Taneja S . Fecal microbiota transplantation in alcohol-associated acute-on-chronic liver failure: an open-label clinical trial. Hepatol Int. 2022; 16(2):433-446. DOI: 10.1007/s12072-022-10312-z. View

10.

Dalal R, McGee R, Riordan S, Webster A . Probiotics for people with hepatic encephalopathy. Cochrane Database Syst Rev. 2017; 2:CD008716. PMC: 6464663. DOI: 10.1002/14651858.CD008716.pub3. View

11.

Riquelme E, Zhang Y, Zhang L, Montiel M, Zoltan M, Dong W . Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes. Cell. 2019; 178(4):795-806.e12. PMC: 7288240. DOI: 10.1016/j.cell.2019.07.008. View

12.

Mukherjee S, Partch C, Lehotzky R, Whitham C, Chu H, Bevins C . Regulation of C-type lectin antimicrobial activity by a flexible N-terminal prosegment. J Biol Chem. 2008; 284(8):4881-8. PMC: 2643518. DOI: 10.1074/jbc.M808077200. View

13.

Grander C, Grabherr F, Spadoni I, Enrich B, Oberhuber G, Rescigno M . The role of gut vascular barrier in experimental alcoholic liver disease and A. muciniphila supplementation. Gut Microbes. 2020; 12(1):1851986. PMC: 7714498. DOI: 10.1080/19490976.2020.1851986. View

14.

Inagaki T, Moschetta A, Lee Y, Peng L, Zhao G, Downes M . Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci U S A. 2006; 103(10):3920-5. PMC: 1450165. DOI: 10.1073/pnas.0509592103. View

15.

Roychowdhury S, Glueck B, Han Y, Mohammad M, Cresci G . A Designer Synbiotic Attenuates Chronic-Binge Ethanol-Induced Gut-Liver Injury in Mice. Nutrients. 2019; 11(1). PMC: 6357124. DOI: 10.3390/nu11010097. View

16.

Spadoni I, Zagato E, Bertocchi A, Paolinelli R, Hot E, Di Sabatino A . A gut-vascular barrier controls the systemic dissemination of bacteria. Science. 2015; 350(6262):830-4. DOI: 10.1126/science.aad0135. View

17.

Cani P, Bibiloni R, Knauf C, Waget A, Neyrinck A, Delzenne N . Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. 2008; 57(6):1470-81. DOI: 10.2337/db07-1403. View

18.

Depommier C, Everard A, Druart C, Plovier H, Van Hul M, Vieira-Silva S . Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med. 2019; 25(7):1096-1103. PMC: 6699990. DOI: 10.1038/s41591-019-0495-2. View

19.

Smirnova E, Puri P, Muthiah M, Daitya K, Brown R, Chalasani N . Fecal Microbiome Distinguishes Alcohol Consumption From Alcoholic Hepatitis But Does Not Discriminate Disease Severity. Hepatology. 2020; 72(1):271-286. PMC: 7752764. DOI: 10.1002/hep.31178. View

20.

Wirbel J, Pyl P, Kartal E, Zych K, Kashani A, Milanese A . Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer. Nat Med. 2019; 25(4):679-689. PMC: 7984229. DOI: 10.1038/s41591-019-0406-6. View